Kevin Kunzmann

In results reported at the European Academy of Dermatology and Venereology Congress, two-week and four-week doses of the subcutaneous drug proved efficacious in improving patient skin.

Investigators reported an overall mean estimation error ranging from 3.47% to 5.29% in five-year outcomes for patients with AMD.

The FDA approved the Teva Pharmaceutical drug, just months after its phase 3 program for headache clusters was discontinued.

Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.

The acceptance comes less than a month since the FDA had approved the anti-VEGF therapy for the treatment of wet AMD. Its mechanism of action allows it to block new blood vessel growth and the passing of fluids through blood vessels in the eye.

The company’s application for mepolizumab vied for it to serve as an add-on therapy to inhaled corticosteroid-based maintenance treatment in patients with COPD, as guided by patient blood eosinophil counts.

The sublingual film therapy has been approved under a 16 mg/ 4 mg dosage strength for the maintenance treatment of opioid dependence, adding to therapy options which include both brand name and generic versions.

With another randomized, controlled trial involving patients at high risk for flu complications currently underway, investigators found that baloxavir may provide an option for patients with uncomplicated influenza.

The CDC reports that, while tobacco use has decreased, cardiovascular disease risk factors and rates of cardiovascular management are still in need of improvement.

The therapy’s New Drug Application was accepted and granted Priority Review in May of this year, after having been granted Breakthrough Therapy designation in September 2016.

Ticagrelor 60 mg and 90 mg tablets have been indicated for lowering the risk of heart attack, or death from heart attack or stroke in patients with acute coronary syndrome.

More than 2 million US outpatient visits and 3 million emergency department visits from 2005-2009 were accounted to children seeking care for mild TBI. Until now, no evidence-based clinical guidelines for pediatric mild TBI existed.

The principles included new and updated evidence over recent years in the field of diabetes self-management, education, and support, as well as shared decision-making skills and individualized care for patients.

The heart rhythm specialist with the UVA Advanced Imaging group discussed his team's early successes with Medtronic's heart ablation vest.

Among patients who were lost to follow-up over a year, just 7.4% attended a follow-up visit after the observed 12 months. In the total loss to follow-up patient population, they reported a mean 7.8 injection treatments and 8.5 clinic visits. In patients not lost, they reported a mean 14.3 injections and 17.1 visits.

DELSTRIGO and PIFELTRO have been indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience.

15 years ago, the Los Angeles-based educator and public health professional introduced Canary Health with his son. Here’s how the father-son team improved diabetes management online.

In a phase 2/3 trial, the Bayer Pharmaceuticals therapy demonstrated protection from bleeding and patient safety for up to a median of 1.9 years.

A class of drugs indicated for use with diet and exercise in patients with type 2 diabetes, has been linked to necrotizing fasciitis of perineum (Fournier’s gangrene).

The COMPASS-XT five-year analysis reported that patients treated with the micro-stent experienced statistically significant loss of endothelial cells compared to the patients treated with lone cataract surgery.

In 2016, US firearm suicides represented 35.3% of all global firearm suicides—despite the US just comprising 4.3% of the global population.

Relevant cIAI diagnoses include intra-abdominal abscess, stomach perforation, peritonitis, appendicitis, and more. Eravacycline's efficacy and safety were established in non-inferiority studies comparing it to the widely-used therapies ertapenem and meropenem.

Patients administered the FDA-approved therapy reported tripled rates of weight-loss, along with noninferiority for risk of major cardiovascular events, over 1 year and an extension period.

The update reported significant improvements in future cardiovascular risks in patients at risk for chronic angina initially referred for CTA plus standard care, versus those only referred to standard care.

The phase 2b dose-ranging trial will involve 216 patients across 12-15 research sites in North America and Europe, beginning in the UK later this month.

The Kala Pharmaceuticals therapy INVELTYS becomes the first twice-daily ocular corticosteroid indicated for such treatment.

In a clinical trial, the expedited Transcranial Magnetic Stimulation device produced a patient response/remission rates of 32% depressive symptom improvement rates of 49%.

Cleveland Clinic investigators have discovered a novel form of the neurological condition which does not demyelinate the brain's white matter.

Quebec-based investigators have highlighted the central role of bridge symptoms in the developmental process leading to long-term anxiety.

The director of Pain Management and Palliative Care at the Englewood Hospital & Medical Center in Englewood, NJ, explains how analgesics may come to the forefront of pain management care.